Mcp-1 predicts recurrent cardiovascular events in patients with persistent inflammation
| Autor: | Carlos Gutiérrez-Landaluce, Ana María Pello Lázaro, Óscar González-Lorenzo, José Luis Martín-Ventura, Ana Huelmos, Carmen Cristóbal, Ester Canovas, Álvaro Aceña, Óscar Lorenzo, Lorenzo López Bescós, Juan Martínez-Milla, Andrea Kallmeyer, Jesús Egido, Nerea Méndez-Barbero, Marta López-Castillo, Luis Miguel Blanco-Colio, Joaquín Alonso, José Tuñón, Nieves Tarín |
|---|---|
| Přispěvatelé: | UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Servicio de Cardiología. Hospital Universitario de Fuenlabrada |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Acute coronary syndrome
medicine.medical_specialty Medicina lcsh:Medicine Inflammation Disease 030204 cardiovascular system & hematology Gastroenterology Article C-reactive protein Coronary artery disease 03 medical and health sciences 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine cardiovascular diseases Stroke Chemokine CCL2 Quimiocina CCL2 Enfermedades Cardiovasculares biology Inflamación business.industry lcsh:R General Medicine medicine.disease Brain natriuretic peptide Cardiovascular Diseases NT-proBNP Heart failure biology.protein medicine.symptom business MCP-1 |
| Zdroj: | Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid instname Journal of Clinical Medicine, Vol 10, Iss 1137, p 1137 (2021) Biblos-e Archivo. Repositorio Institucional de la UAM Journal of Clinical Medicine Volume 10 Issue 5 |
| Popis: | Clinical data indicate that patients with C-reactive protein (CRP) levels higher than 2 mg per liter suffer from persistent inflammation, which is associated with high risk of cardiovascular disease (CVD). We determined whether a panel of biomarkers associated with CVD could predict recurrent events in patients with low or persistent inflammation and coronary artery disease (CAD). We followed 917 patients with CAD (median 4.59 ± 2.39 years), assessing CRP, galectin-3, monocyte chemoattractant protein-1 (MCP-1), N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin-I plasma levels. The primary outcome was the combination of cardiovascular events (acute coronary syndrome, stroke or transient ischemic event, heart failure or death). Patients with persistent inflammation (n = 343) showed higher NT-proBNP and MCP-1 plasma levels compared to patients with CRP < 2 mg/L. Neither MCP-1 nor NT-proBNP was associated with primary outcome in patients with CRP < 2 mg/L. However, NT-proBNP and MCP-1 plasma levels were associated with increased risk of the primary outcome in patients with persistent inflammation. When patients were divided by type of event, MCP-1 was associated with an increased risk of acute ischemic events. A significant interaction between MCP-1 and persistent inflammation was found (synergy index: 6.17 (4.39–7.95)). In conclusion, MCP-1 plasma concentration is associated with recurrent cardiovascular events in patients with persistent inflammation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|